The rapid rise of companies like OpenAI and Anthropic to trillion-dollar valuations in under five years is a rare "punctuated equilibrium" event. Founders and investors should not expect this unprecedented speed to become the standard for the next wave of companies.
Investors often fail to grasp the true market size of AI companies by applying old SaaS "per-seat" logic. The real opportunity lies in rethinking TAM based on outcome-based pricing and value-based consumption, which can create 100x larger markets than traditional proxies suggest.
A concerning trend is emerging where talented founders, fearing competition from major AI labs, are choosing to build in smaller, niche markets. This flight to perceived safety may limit the creation of ambitious, market-defining companies and represents a misallocation of top talent.
To combat the emotional biases around selling, founders should proactively schedule an annual board meeting dedicated to rationally discussing a potential exit. This normalizes the conversation and ensures strategic decisions are made based on market timing and opportunity cost, not just momentum.
When considering an exit, the primary risk isn't financial; it's the founder's time locked in a stagnating company. Spending productive years on a venture that's not working—even if well-funded—prevents a talented founder from pursuing the next big thing during a period of rapid technological change.
The pervasive belief within AI labs that Recursive Self-Improvement (RSI) is just 18 months away is creating a manic, high-intensity work environment. This "last chance to contribute" mentality is causing researchers to question major life decisions and risks a massive burnout cycle across the industry.
As compute becomes the primary bottleneck, AI labs will shift from broad access to a strategic allocation model. They will measure the "Return on Invested Tokens" (ROIT) to ensure their most scarce resource is given to the small subset of researchers who drive the majority of progress.
The push for AI regulation risks repeating mistakes made in pharmaceuticals, where a singular focus on safety, without balancing it against potential benefits, led to regulatory capture and slowed progress. This could cripple AI's potential for societal good in healthcare, energy, and more.
Even if AI displaces some engineers at tech giants, these individuals represent a massive talent upgrade for traditional enterprises. Companies in sectors like manufacturing or energy, which struggle to recruit tech talent, will eagerly hire these "mediocre" but highly skilled engineers.